FDA Has Approved First Therapy for MCT8 Deficiency

The drug Emcitate offers a new treatment option for individuals living with this rare genetic disorder.

Updated on Sept. 28, 2026 in Allergies

Isometric editorial illustration featuring geometric representations of a chemical compound, a glass dropper, and a cellular membrane structure. — The FDA approved Emcitate on Tuesday, marking the first time the agency has authorized a therapy specifically for individuals with the rare genetic disorder MCT8 deficiency. AI Illustration. Upload story photo >

Live Poll

Should federal regulators prioritize the expedited approval of treatments for rare genetic diseases?

The FDA approved Emcitate to treat MCT8 deficiency, making it the first authorized therapy for this rare genetic condition that primarily affects males. The medication is delivered as an oral suspension to manage symptoms.

Why it matters

Patients with MCT8 deficiency lack the protein necessary to transport thyroid hormone into the brain, leading to metabolic and cardiovascular complications. This approval provides the first targeted clinical option for managing the condition.

In two clinical studies, the medication tiratricol demonstrated a reduction in excess thyroid hormone levels in the blood. Patients treated with the drug also exhibited improvements in cardiovascular and metabolic symptoms.

The players

FDA

The United States federal agency responsible for protecting public health by ensuring the safety and efficacy of human drugs.

Egetis Therapeutics US Inc.

The pharmaceutical company responsible for the development and regulatory approval of Emcitate.

The details

MCT8 deficiency occurs when the body fails to produce the protein required to carry thyroid hormone into the brain. Emcitate functions by entering cells without relying on the MCT8 transporter, allowing for the regulation of hormone levels. The drug is administered once daily either by mouth or through a feeding tube, with reported side effects including diarrhea, vomiting, rash, and excessive sweating.

September 28, 2026: The FDA approved Emcitate for the treatment of MCT8 deficiency.

Health Landscape

This approval marks the first time a therapeutic intervention has been cleared for the treatment of MCT8 deficiency in the United States. It follows the established regulatory pathway for orphan drug designation, addressing a significant gap in care for rare genetic disorders.

If you or a family member are living with MCT8 deficiency, this approval represents a new treatment avenue to discuss with your primary care physician or specialist. It is important to review the full safety profile and potential side effects with your medical team before considering this therapy.

The takeaway

Emcitate represents a significant development as the first FDA-approved treatment for the metabolic and cardiovascular symptoms of MCT8 deficiency. Patients and families should work closely with their medical specialists to determine if this new once-daily therapy is appropriate for their care plan.